87
Views
10
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Insight into pimecrolimus experience in seborrheic dermatitis: Close follow-up with exact mean cure and remission times and side-effect profile

, &
Pages 198-202 | Received 26 Nov 2008, Accepted 02 Dec 2008, Published online: 12 Jul 2009
 

Abstract

Background: Pimecrolimus was found to be effective for the treatment of seborrheic dermatitis in several studies and its off-label use is increasing gradually. Objectives: This study was conducted to obtain more detailed information concerning the daily use of pimecrolimus in seborrheic dermatitis and it also aims to contribute to data for the future construction of guidelines. Methods: A total of 52 patients with seborrheic dermatitis enrolled in the study. Pimecrolimus 1% cream was applied twice daily. The mean cure and remission times, detailed responses of each clinical finding and side effects were investigated. Results: The mean cure and mean remission times were 13.34 and 47.98 days, respectively. Disease severity improved by 50% in between the third and seventh days. Pruritus responded first to pimecrolimus. The drug was equally effective for erythema and scaling. The most frequent side effect was the burning–tingling sensation. After the seventh day of the study, there was no side effect. Conclusions: Pimecrolimus applications for the treatment of seborrheic dermatitis provide a complete cure in a short period of time and a sustained symptom-free period with low and self-limited side effects.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access
  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart
* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.